Balgrist University Hospital

balgrist.ch

Total trials

80

Active

11

Phase 3

6

Total enrollment

11,444

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 4 of 4 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
NaCl 0.9%2
Standard antibiotic prophylaxis1
Dexamethasone 4 Mg/mL Injectable Solution1
duration of standard antibiotic therapy1

Next readouts

  • 2024-07-31
  • 2024-12-12
  • 2025-02-28

Top conditions

  • Neck Pain4
  • Sarcoma3
  • Rotator Cuff Tear3
  • Low Back Pain3
  • Healthy3
  • Soft Tissue Sarcoma2
  • Sarcoma of Bone2
  • Osteoarthritis, Knee2

Frequently asked questions about Balgrist University Hospital

How many clinical trials does Balgrist University Hospital have on ClinicalTrials.gov?
Balgrist University Hospital is listed as the lead sponsor on 80 clinical trials in ClinicalTrials.gov, 11 of which are currently active (recruiting, enrolling, or ongoing).
How many of Balgrist University Hospital's trials are in Phase 3?
6 of Balgrist University Hospital's trials are in Phase 3, spread across 4 active drug programs.
What therapeutic areas does Balgrist University Hospital focus on?
Balgrist University Hospital's most-studied conditions on ClinicalTrials.gov are Neck Pain, Sarcoma, Rotator Cuff Tear, Low Back Pain, Healthy.
When are Balgrist University Hospital's next clinical trial readouts?
Balgrist University Hospital has 3 upcoming primary-completion readouts tracked here; the soonest is “Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Periacetabular Osteotomy”, expected around 2024-07-31.